Effect of CTLA-4-Ig on human B lymphocyte function and specificity for citrullinated protein antigens in rheumatoid arthritis (RA)

Effect of CTLA-4-Ig on human B lymphocyte function and specificity for citrullinated protein antigens in rheumatoid arthritis (RA) - Abatacept and B cells

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012864

Enrollment

Registered

2017-08-07

Start date

2017-08-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Group 1: In this study we assess in vitro the effect of CTLA-4-Ig in a T-cell free system on the development of naive B cells to memory B cells and plasmablasts. Furthermore, we assess in patients w

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: rheumatoide arthritis informed consent treatment with abatacept treatment start after 01.01.2015

Exclusion criteria

Exclusion criteria: prior therapy with ritxuimab, JAk-Inhibitors, cyclophosphamide malignant disease

Design outcomes

Primary

Measure	Time frame
Changes in B cell compartment and titers of autoantibodies: - blood specimens drawn 3, 6 and 12 month after start of therapy will be analyzed for a, B cell subpopulations (naive, marginal zone, memory) b, titers of ccP-antibodies	—

Secondary

Measure	Time frame
Changes in ACPA reactivity 3,6 and 12 months after start of therapy	—

Countries

Germany

Contacts

Public ContactJens Thiel

Uniklinik Freiburg

jens.thiel@uniklinik-freiburg.de076127034210

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026